Recent advances in filovirus- And arenavirus-like particles

Future Virology

Volumn 2, Issue 2, 2007, Pages 193-203

  Hoenen, Thomas ^a   Kolesnikova, Larissa ^a   Becker, Stephan ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Arenaviruses; Filoviruses; Infectious virus like particles; Late domains; Vaccine; Virus like particles

Indexed keywords

ARENAVIRUS VACCINE; FILOVIRUS VACCINE; MATRIX PROTEIN; NUCLEOCAPSID PROTEIN; PROTEIN VP24; PROTEIN VP40; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ARENAVIRUS; DNA PACKAGING; ENDOSOME; FILOVIRUS; GENE STRUCTURE; HEMORRHAGIC FEVER; HUMAN; INNATE IMMUNITY; LIFE CYCLE; MOLECULAR BIOLOGY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SYMPTOMATOLOGY; VACCINATION; VIRAL GENETICS; VIRION; VIROGENESIS; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ARENAVIRUS; MARBURGVIRUS;

EID: 34249333130     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.2.193     Document Type: Review

References (73)

1. Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW: Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med. 5, 761-772 (2005).
2. Feldmann H, Geisbert TW, Jahrling PB et al.: In: Virus Taxonomy, Eighth Report of the International Committee on Taxonomy of Viruses. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (Eds). 645-653, Elsevier/Academic Press, San Diego, USA (2005).
3. Wang L, Harcourt BH, Yu M et al.: Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3, 279-287 (2001).
4. Towner JS, Khristova ML, Sealy TK et al.: Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497-6516 (2006).
5. Sanchez A, Rollin PE: Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda. Virus Res. 113, 16-25 (2005).
6. Groseth A, Ströher U, Theriault S, Feldmann H: Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. Virus Res. 87, 155-163 (2002).
7. Ikegami T, Calaor AB, Miranda ME et al.: Genome structure of Ebola virus subtype Reston: differences among Ebola subtypes. Brief report. Arch. Virol. 146, 2021-2027. (2001).
8. Biacchesi S, Skiadopoulos MH, Boivin G et al.: Genetic diversity between human metapneumovirus subgroups. Virology 315, 1-9 (2003).
9. Kuhn JH, Radoshitzky SR, Guth AC et al.: Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J. Biol. Chem. 281, 15951-15958 (2006).
10. Jasenosky LD, Kawaoka Y: Filovirus budding. Virus Res. 106, 181-188 (2004).
11. Feldmann H, Volchkov VE, Volchkova VA, Ströher U, Klenk HD: Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 82, 2839-2848. (2001).
12. Hartlieb B, Weissenhorn W: Filovirus assembly and budding. Virology 344, 64-70 (2006).
13. Bamberg S, Kolesnikova. L, Möller P, Klenk HD, Becker S: VP24 of Marburg virus influences formation of infectious particles. J. Virol. 79, 13421-13433 (2005).
14. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN: Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77, 1793-1800 (2003).
15. Licata JM, Johnson RF, Han Z, Harty RN: Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78, 7344-7351 (2004).
16. Hoenen T, Groseth, A, Kolesnikova L et al.: Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J. Virol. 80, 7260-7264 (2006).
17. Noda T, Aoyama K, Sagara H, Kida H, Kawaoka Y: Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography J. Vet. Med. Sci. 67, 325-328 (2005).
18. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD: Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277, 147-155 (2000).
19. Reid SP, Leung LW, Hartman AL et al.: Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. J. Virol. 80, 5156-5167 (2006).
20. Ebihara H, Takada A, Kobasa D et al.: Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73 (2006).
21. Mühlberger E, Becker S: Marburg virus replication and nucleocapsid formation: different jobs, same players. In: Structure-Function Relationships of Human Pathogenic Viruses. Bogner E, Holzenburg A (Eds.) 89-97, Kluwer Academic/Plenum Publishers, London, UK (2002).
22. Kolesnikova L, Mühlberger E, Ryabchikova E, Becker S: Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions. J. Virol. 74, 3899-3904 (2000).
23. Noda T, Ebihara H, Muramoto Y et al.: Assembly and budding of Ebolavirus. PLoS Pathog. 2, e99 (2006).
24. Mühlberger E, Lötfering B, Klenk HD, Becker S: Three of the four nucleocapsid proteins of Marburg virus, NP, VP35 and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J. Virol. 72, 8756-8764 (1998).
25. Mühlberger E, Weik M, Volchkov VE, Klenk HD, Becker S: Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333-2342 (1999).
26. Cardenas WB, Loo YM, Gale M Jr et al.: Ebola virus VP35 protein binds double-stranded RNA and inhibits α/β interferon production induced by RIG-I signaling. J. Virol. 80, 5168-5178 (2006).
27. Hartman AL, Dover JE, Towner JS, Nichol ST: Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80, 6430-6440 (2006).
28. Feng Z, Cerveny M, Yan Z, He B: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA dependent protein kinase PKR. J. Virol. 81, 182-193 (2006).
29. Volchkov VE, Volchkova VA, Mühlberger E et al.: Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291, 1965-1969. (2001).
30. Kindzelskii AL, Yang Z, Nabel GJ, Todd RF 3rd, Petty HR: Ebola virus secretory glycoprotein (sGP) diminishes Fc γ RIIIB-to-CR3 proximity on neutrophils. J. Immunol 164, 953-958 (2000).
31. Sui J, Marasco WA: Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 303, 9-14 (2002).
32. Wahl-Jensen V, Kurz SK, Hazelton PR et al.: Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 79, 2413-2419 (2005).
33. Whelan SP, Barr JN, Wertz GW: Transcription and replication of nonsegmented negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 283, 61-119 (2004).
34. Mavrakis M, Kolesnikova L, Schoehn G, Becker S, Ruigrok RW Morphology of Marburg virus NP-RNA. Virology 296, 300-307 (2002).
35. Huang Y, Xu L, Sun Y, Nabel GJ: The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and post-translational modification of nucleoprotein. Mol. Cell. 10, 307-316 (2002).
36. Watanabe S, Noda T, Kawaoka Y: Functional mapping of the nucleoprotein of Ebola virus. J. Virol. 80, 3743-3751 (2006).
37. Noda T, Watanabe S, Sagara H, Kawaoka Y: Mapping of the VP40-binding regions of the Nucleoprotein of Ebola virus. J. Virol. (2007) (Epub ahead of print).
38. Johnson RF, McCarthy SE, Godlewski PJ, Harty RN: Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J. Virol. 80, 5135-5144 (2006).
39. Boehmann Y, Enterlein S, Randolf A, Mühlberger E: A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology 332, 406-417 (2005).
40. Groseth A, Feldmann H, Theriault S, Mehmetoglu G, Flick R: RNA polymerase I-driven minigenome system for Ebola viruses. J. Virol. 79, 4425-4433 (2005).
41. Conzelmann KK: Reverse generics of mononegavirales. Curr. Top. Microbiol. Immunol. 283, 1-41 (2004).
42. Becker S, Rinne C, Hofsäss U, Klenk HD, Mühlberger E: Interactions of Marburg virus nucleocapsid proteins. Virology 249, 406-417 (1998).
43. Möller P, Pariente N, Klenk HD, Becker S: Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J. Virol. 79, 14876-14886 (2005).
44. Reid SP, Cardenas WB, Basler CF: Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology 341, 179-189 (2005).
45. Poch O, Blumberg BM, Bougueleret L, Tordo N: Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA vinises: theoretical assignment of functional domains. J. Gen. Virol. 71, 1153-1162. (1990).
46. Calain P, Monroe MC, Nichol ST: Ebola virus defective interfering particles and persistent infection. Virology 262, 114-128. (1999).
47. Crary SM, Towner JS, Honig JE, Shoemaker TP, Nichol ST: Analysis of the role of predicted RNA secondary structures in Ebola virus replication. Virology 306, 210-218. (2003).
48. Weik M, Enterlein S, Schletiz; K, Mühlberger E: The Ebola virus genomic replication promoter is bipartite and follows the rule of six. J. Virol. 79, 10660-10671 (2005).
49. Cowton VM, McGivern DR, Fearns R: Unravelling the complexities of respiratory syncytial virus RNA synthesis. J. Gen. Virol. 87, 1805-1821 (2006).
50. Kolakofsky D, Roux L, Garcin D, Ruigrok RW: Paramyxovirus mRNA editing, the 'rule of six' and error catastrophe: a hypothesis. J. Gen. Virol. 86, 1869-1877 (2005).
51. Weik M, Modrof J, Klenk HD, Becker S, Mühlberger E: Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J. Virol. 76, 8532-8539. (2002).
52. Mühlberger E, Trommer S, Funke C, Volchkov V, Klenk HD, Becker S: Termini of all mRNA species of Marburg virus: sequence and secondary structure. Virology 223, 376-380 (1996).
53. Mühlberger E: Genome organization, replication, and transcription of filoviruses. In: Ebola and Marburg viruses: Molecular and Cellular Biology. Feldmann HaK, HD (Eds). 1-12, Horizon Scientific Press, Wymondham, Norfok UK (2004).
54. Sanchez A, Kiley MP, Holloway BP, Auperin DD: Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 29, 215-240 (1993).
55. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y: Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 76, 406-410 (2002).
56. Theriault S, Groseth A, Neumann G, Kawaoka Y, Feldmann H: Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res. 106, 43-50 (2004).
57. Modrof J, Mühlberger E, Klenk HD, Becker S: Phosphorylation of VP30 impairs ebola virus transcription. J. Biol. Chem. 277, 33099-33104. (2002).
58. Modrof J, Becker S, Mühlberger E: Ebola virus transcription activator VP30 is a zinc-binding protein. J. Virol. 77, 3334-3338 (2003).
59. Hartlieb B, Modrof J, Mühlberger E, Klenk HD, Becker S: Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J. Biol. Chem. 278, 41830-41836 (2003).
60. Hartlieb B, Muziol T, Weissenhorn W, Becker S: Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc. Natl. Acad. Sci. USA 104, 624-629 (2007).
61. Hardy RW, Wertz GW: The Cys(3)-His(1) motif of the respiratory syncytialvirus M2-1 protein is essential for protein function. J. Virol. 74, 5880-5885 (2000).
62. Enterlein S, Volchkov V, Weik M et al.: Rescue of recombinant Marburg vinis from cDNA is dependent on nucleocapsid protein VP30. J. Virol. 80, 1038-1043 (2006).
63. Fowler T, Bamberg S, Möller P et al.: Inhibition of Marburg virus protein expression and viral release by RNA interference. J. Gen. Virol. 86, 1181-1188 (2005).
64. Volchkov VE, Becker S, Volchkova VA et al.: GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214, 421-430 (1995).
65. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST: The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl Acad Sci. USA 93, 3602-3607 (1996).
66. Alazard-Dany N, Volchkova V, Reynard O et al.: Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J. Gen. Virol. 87, 1247-1257 (2006).
67. Geisbert TW, Hensley LE, Kagan E et al.: Postexposure protection of guinea pigs against a Lethal ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193, 1650-1657 (2006).
68. Warfield KI, Swenson DI, Olinger GG et al.: Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2, e1 (2006).
69. Enterlein S, Warfield KL, Swenson DL et al.: VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50, 984-993 (2006).
70. Müller S, Möller P, Bick MJ et al.: Inhibition of filovirus replication by the zinc finger antiviral protein. J. Virol. 81(5), 2391-2400 (2006).
71. Kash JC, Mühlberger E, Carter V et al.: Global suppression of the host antiviral response by Ebola- and Marburg viruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80, 3009-3020 (2006).
72. Watanabe S, Watanabe T, Noda T et al.: Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J. Virol. 78, 999-1005 (2004).
73. Towner JS, Paragas J, Dover JE et al.: Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332, 20-27 (2005).